Key Details
Price
$25.36Annual ROE
-150.08%Beta
1.14Events Calendar
Next earnings date:
Feb 13, 2025Recent quarterly earnings:
Nov 6, 2024Recent annual earnings:
Feb 15, 2024Next ex-dividend date:
N/ARecent ex-dividend date:
N/ANext split:
N/ARecent split:
N/AAnalyst ratings
Recent major analysts updates
Market Data
Price
Market cap
Technical
Dividend
Profitability
Revenue
Profit
EPS
ROA & ROE
EBIT & EBITDA
Valuation
PE Ratio
PB Ratio
PS Ratio
Enterprise value
EV/EBITDA
Financial Health
Liquidity
Leverage
Risk & Stability
Balance Sheet
Assets
Equity
Liabilities
Debt
Expenses
Cash Flow
Cashflow Activities
Free CashFlow
CAPEX
Institutional Ownership
Cellebrite DI LTD (CLBT) provides special digital investigation tools for government agencies and has seen its stock rise by 172% in the last year. The company aims for a 24% annual growth rate in recurring revenue and a 20% growth rate in total revenue by 2028, while also improving profit margins since 2022. Although there may be a temporary drop in stock prices, CLBT's low short interest and diverse international customers, particularly in fast-growing markets, help reduce long-term risks.
Cellebrite DI is a leading company in digital forensics, facing high entry barriers and experiencing strong growth, positive free cash flow, and a solid financial position. It provides services to major police departments and Fortune 100 companies, with plenty of opportunities for expansion and high switching costs linked to security clearances and data. The company's advantages include easy-to-use digital investigation tools, advanced methods for breaking phone encryption, and AI features, making it crucial for law enforcement agencies.
Cellebrite Endpoint Inspector Solutions are now officially available in RelativityOne. You can now access these solutions within the platform.
Investors interested in the Technology Services sector may want to look at Nu Holdings Ltd. (NU) or Cellebrite DI Ltd. as potential stock options.
I had previously given Cellebrite DI a 'strong buy' rating because of its potential for growth and good value. Since then, the stock has done very well, increasing by 160%, while the S&P 500 only went up by 33%. Additionally, Cellebrite has shown positive results in its Q3 2024 earnings report.
I have a neutral opinion on Cellebrite because of its high valuation and the risks associated with the change in CEO and possible federal budget cuts. Although the company has shown good growth, with a 27% rise in revenue and improving profit margins, the uncertainties regarding leadership and government funding affect my view. The strong uptake of products like Inseyets, Guardian, and Pathfinder, along with significant annual recurring revenue growth, indicates that there is still a lot of potential for future growth.
Cellebrite DI Ltd. (CLBT) reported quarterly earnings of $0.14 per share, which is higher than the Zacks Consensus Estimate of $0.11 per share.
In the third quarter of 2024, the company achieved a revenue of $106.9 million, surpassing the $100 million mark for quarterly revenue for the first time ever. This is a significant milestone in the company's history.
Cellebrite, a leading company in Digital Investigative solutions, has announced a change in leadership. Yossi Carmil will resign from his position as CEO and leave the Board of Directors by December 31, 2024. This announcement was made on November 6, 2024, from Tysons Corner, Virginia, and Petah Tikva, Israel.
Cellebrite DI Ltd. (CLBT) could see an increase in its stock price due to rising confidence in its earnings potential, as shown by its upgrade to a Zacks Rank #1 (Strong Buy).
FAQ
- What is the ticker symbol for Cellebrite DI?
- Does Cellebrite DI pay dividends?
- What sector is Cellebrite DI in?
- What industry is Cellebrite DI in?
- What country is Cellebrite DI based in?
- When did Cellebrite DI go public?
- Is Cellebrite DI in the S&P 500?
- Is Cellebrite DI in the NASDAQ 100?
- Is Cellebrite DI in the Dow Jones?
- When was Cellebrite DI's last earnings report?
- When does Cellebrite DI report earnings?
- Should I buy Cellebrite DI stock now?